The Court of appeal of Lyon has recognized this Thursday that Merck had committed “a fault” at the time of the change of formula of its treatment Levothyrox.
The Court of appeal of Lyon has recognized this Thursday that Merck had committed “a fault” at the time of the change of formula of its treatment Levothyrox.
If any 800 users Levothyrox had abandoned the procedure after the first-instance decision, 3 329 the plaintiffs had decided to continue their fight on appeal in the face of Merck. And they have won. The Court of appeal of Lyon has sentenced this Thursday the pharmaceutical laboratory to pay 1 000 euros to each of the complainants under the heading of “moral damage”, stated their lawyer.
The court has declared admissible the call of civil parties and (…) has held that Merck had committed a fault”, said to the press, Me Christophe Leguevaques, about changing the formula of its treatment Levothyrox. According to him, the laboratory “had a legal obligation to inform directly the sick, in particular by the box and the leaflet”.
The legal director of Merck, Florent Bensadoun, has considered this decision “totally incomprehensible” and said the company would lodge an appeal.
Your support is essential. Subscribe for $ 1 support Us
READ ALSO >> Levothyrox : end of the marketing of the old formula in September
In the first instance, the complainants had been rejected, the judges lyonnais dismissing any fault of Merck in the launch in 2017 of the new Levothyrox, that its users accused of causing multiple side effects.
“The important thing for the civil parties was that their situation, their pain, their unhappiness, to be recognized by the Justice,” welcomed Me Leguevaques. They clamored for tune compensation of 10 000 euro per person – or 33 million euros in total. During the call, the pharmaceutical industry has kept the same line of defence, and reiterated that it could not provide information directly to patients. Prohibited by law.
Insomnia, dizziness…
The new formula of the drug prescribed for hypothyroidism, modifying some of its excipients in order to bring more stability to the product, has been accused, between march 2017 and April 2018, by some 31 000 patients suffering from headache, insomnia, dizziness, etc
In June 2019, the Agency of the drug/MSNA published the results of a study of pharmaco-epidemiology conducted on more than two million patients, according to which the transition to the new formula of the Levothyrox did not cause “serious health problems”.
an estimated 2.5 million patients are using the new formula of the Levothyrox according to Merck, “less than 100,000” taking the old formula imported from by the end of 2017 under the name Euthyrox. Five alternatives to basic levothyroxine is also available on the market.
For the lab, the rising adverse effects on the new formula are now “normal and comparable to the old”. France was the first country where this formula was introduced. Since then, it has been in fifteen countries of the european Union, without difficulty, adds Merck.
The case is the subject, a criminal, a judicial investigation against X, educated by the health division of the TGI of Marseille for alleged aggravated tort of deceit, homicide, and unintentional injury and endangering the life of others.
Date Of Update: 25 June 2020, 10:58
Categories: Optical Illusion
Source: newstars.edu.vn